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receptor positive, HER2 amplified, and tamoxifen
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Armine Matevossian1,2 and Marilyn D Resh1,2*Abstract
Background: Hedgehog acyltransferase (Hhat) catalyzes the transfer of the fatty acid palmitate onto Sonic
Hedgehog (Shh), a modification that is essential for Shh signaling activity. The Shh signaling pathway has been
implicated in the progression of breast cancer.
Methods: To determine the functional significance of Hhat expression in breast cancer, we used a panel of breast
cancer cell lines that included estrogen receptor (ER) positive, HER2 amplified, triple negative, and tamoxifen
resistant cells. We monitored both anchorage dependent and independent proliferation of these cells following
depletion of Hhat with lentiviral shRNA and inhibition of Hhat activity with RU-SKI 43, a small molecule inhibitor
of Hhat.
Results: Depletion of Hhat decreased anchorage-dependent and anchorage-independent proliferation of ER
positive, but not triple negative, breast cancer cells. Treatment with RU-SKI 43 also reduced ER positive cell
proliferation, whereas a structurally related, inactive compound had no effect. Overexpression of Hhat in ER
positive cells not only rescued the growth defect in the presence of RU-SKI 43 but also resulted in increased
cell proliferation in the absence of drug. Furthermore, depletion or inhibition of Hhat reduced proliferation of
HER2 amplified as well as tamoxifen resistant cells. Inhibition of Smoothened had no effect on proliferation,
indicating that canonical Shh signaling was not operative. Moreover, Hhat regulated the proliferation of both
Shh responsive and non-responsive ER positive cells, suggesting a Shh independent function for Hhat.
Conclusions: These data suggest that Hhat plays a critical role in ER positive, HER2 amplified, and hormone
resistant breast cancer proliferation and highlights the potential promise of Hhat inhibitors for therapeutic
benefit in breast cancer.
Keywords: Breast cancer, Hedgehog, Hedgehog acyltransferase, Tamoxifen resistant, PI3K/mTORBackground
Breast cancer is the most common cancer affecting
women [1]. Gene expression profiling has identified dis-
tinct biological subtypes of breast cancer: luminal A or
B, human epidermal growth factor receptor 2 (HER2)
amplified, basal like, and claudin low [2]. The luminal A
and B subtypes are both estrogen receptor (ER) positive
and comprise up to 70% of all breast cancers. Luminal B
tumors are also HER2 positive and have a poorer* Correspondence: reshm@mskcc.org
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article, unless otherwise stated.prognosis [2-4]. The basal like and claudin low subtypes
are both triple negative, lacking expression of ER, HER2
and the progesterone receptor. Treatment of luminal A
tumors with tamoxifen, a selective ER modulator, has
significantly reduced the mortality rate. However, not all
patients respond to tamoxifen and one third of initial re-
sponders have recurrent disease within 15 years [5]. Hor-
mone resistance can occur through ER-dependent as well
as ER-independent mechanisms, including activation of
pro-proliferative signaling pathways such as HER2 and
EGFR [6], PI3K/Akt, and MAPK [7]. Use of trastuzumab,
an antibody targeting HER2, has extended the overall
survival of patients with HER2 amplified tumors [8].d Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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resistance even when treatment is combined with system-
atic chemotherapy [9]. Furthermore, about 70% of initial re-
sponders show progressive disease within a year. Acquired
resistance can occur through overexpression of EGFR fam-
ily receptors [10] or IGF-R1 [11], PTEN loss, or activation
of PI3KCA [12,13]. Therefore, there is a need to identify
new therapeutic targets.
Recently, aberrant activation of the Sonic Hedgehog
(Shh) pathway has been implicated in breast cancer pro-
gression [14-26]. The hedgehog family of secreted signal-
ing molecules includes Shh, Indian and Desert Hedgehog.
Interaction of Shh with the transmembrane receptor
Patched-1 (Ptch-1) relieves inhibition of the transducer
Smoothened (Smo). This leads to the stabilization and
nuclear translocation of the Gli family of transcription
factors [27]. The resulting activation of target gene tran-
scription regulates various cellular processes such as cell
fate determination, proliferation, and survival [27]. A role
for abnormal Shh signaling activity in breast cancer devel-
opment was first reported using transgenic mouse models,
where Ptch-1 haploinsufficiency or ectopic expression of
Smo lead to distinct forms of mammary ductal dysplasia
[28,29]. Furthermore, expression of Gli-1 under the mouse
mammary tumor virus promoter leads to the development
of hyperplastic lesions and tumors [22]. Mutations in Shh,
Ptch, and Smo are rarely identified in human breast can-
cer [23]. Ptch expression is reduced in ductal carcinoma
in situ (DCIS) [29,30], possibly due to increased promoter
methylation [30]. In addition, ectopic expression of Smo
has been identified in both DCIS and invasive breast can-
cer [29]. Breast tumor growth and metastasis in mice is
stimulated by Shh overexpression and is decreased by
inhibiting Shh signaling [14]. In humans, Shh overex-
pression occurs in breast tumor initiating cells and in
invasive ductal carcinoma (IDC), where it is associated
with increased metastasis and death [14]. A progressive
increase in Shh expression correlates with disease progres-
sion from low grade DCIS to IDC [14,15]. In addition,
three studies have noted strong Gli-1 expression in stro-
mal cells [14,18,19]. Shh and Ihh secreted by breast cancer
cells can signal in a paracrine manner to induce osteoclast
differentiation and increase bone resorption [24]. Further-
more, other pathways, including osteopontin and TGFβ,
can also activate Gli-mediated transcription in breast
cancer cells [25,26].
To date, analyses of the hedgehog pathway in breast
cancer have focused mainly on downstream signaling
events. Little is known about components of the path-
way upstream of ligand production. Shh is synthesized
as a precursor protein that undergoes autoprocessing
to produce a ~25 kDa C-terminal fragment and a ~19 kDa
N-terminal fragment (ShhN) that retains all signaling
activity [31,32]. ShhN is modified with two lipids.Cholesterol is covalently attached to the C-terminus dur-
ing the autoprocessing reaction [33]. Cholesterol attach-
ment contributes to long-range signaling activity, but is
not essential for signaling [34]. The N-terminus of ShhN
is modified by covalent attachment of the 16-carbon fatty
acid palmitate to the N-terminal cysteine [35,36]. Shh
palmitoylation is catalyzed by Hedgehog acyltransfer-
ase (Hhat), a multipass transmembrane enzyme that be-
longs to the membrane bound O-acyltransferase (MBOAT)
family [36]. Multiple studies have established that palmi-
toylation of Shh by Hhat is critical for Shh signaling activ-
ity [34,37-40]. Furthermore, Hhat activity is required for
the proliferation of pancreatic cancer cells in vivo and for
the maintenance of a stem-like phenotype in lung squa-
mous cell carcinoma [41-44].
The role of Hhat in breast cancer has not yet been ex-
amined. In this study, we demonstrate that Hhat is re-
quired for the proliferation of ER positive, HER2 positive,
and tamoxifen resistant breast cancer cells. Increased Hhat
expression resulted in increased cell proliferation, while
Hhat depletion reduced proliferation of ER positive cells.
Hhat inhibition with RU-SKI 43, a selective small mol-
ecule inhibitor of Hhat recently identified by our group
[45], also reduced the growth of ER positive cells. Further-
more, Hhat depletion or inhibition led to a significant de-
crease in HER2 positive and tamoxifen resistant cell
proliferation. None of the cell lines we tested responded to
inhibition of Smo, and only a subset responded to Shh
depletion, indicating that non-canonical Shh signaling
pathways were operative. Taken together, these data sug-
gest that Hhat may serve as an important therapeutic tar-
get in ER positive, HER2 amplified, and hormone resistant
breast cancers.
Results
Hhat depletion results in reduced ER positive breast
cancer cell proliferation
To investigate the role of Hhat in breast cancer, we used a
panel of ER positive (T47D, MCF7, HCC1428, CAMA-1,
and BT474) and ER negative (MDA-MB-231, BT549,
Hs578t, and MDA-MB-453) cell lines. ER and HER2
expression status was verified in the above cell lines
(Additional file 1: Figure S1). Hhat mRNA was detected in
all cell lines to varying degrees, with mostly higher expres-
sion in the ER positive cells (Figure 1A). To assess the
functional significance of Hhat expression in breast cancer
cells, two different lentiviral based short hairpin RNAs
were used to stably deplete Hhat mRNA. Hhat depletion
(Additional file 2: Figure S2A) led to a 66% reduction in
proliferation of ER positive T47D cells, compared to the
scrambled shRNA control (Figure 1B). Similar results
were observed in all ER positive cell lines (Figure 1C-F,
Additional file 2: Figure S2B-E). By contrast, depletion of
Hhat in triple negative cells (Additional file 2: Figure S2G-I)
Figure 1 Hhat depletion reduces proliferation of ER positive breast cancer cells. A, Hhat mRNA expression in indicated breast cancer cell
lines and a control cervical cancer (HeLa) cell line, was measured by qRT-PCR. Hhat expression is shown relative to the expression in HeLa cells,
which is set to 1. Bars represent mean ± SD (n = 3). Experiments were performed twice in triplicate. B-J, Total cell number at day 6 for (B) T47D,
(C) MCF7, (D) HCC1428, (E) CAMA-1, (F) BT474, (G) TamR, (H) MDA-MB-231, (I) BT549, and (J) Hs578t. Cells stably expressing scrambled or Hhat
shRNAs were seeded at 5-7 × 104 cells/well, depending on cell type, in 6-well plates and cell numbers were quantified on day 6. For panels B-J,
Bars represent mean ± SD (n = 3). Three independent experiments were performed in duplicate using cells at three different passages. *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Student’s t test.
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tored anchorage independent growth, a hallmark of neo-
plastic cells. Hhat depletion in ER positive, but not in triple
negative, cells resulted in markedly reduced anchorage in-
dependent proliferation (Figure 2A-F). These data indicate
that Hhat regulates anchorage dependent and independent
proliferation of ER positive cells.
Hhat inhibition leads to decreased ER positive breast
cancer cell proliferation
To validate that Hhat activity is required for ER positive
breast cancer cell growth, we used RU-SKI 43, a selective
small molecule inhibitor of Hhat previously identified by
our laboratory [45]. Treatment of T47D cells, which ex-
press relatively high levels of Hhat, with increasing con-
centrations of RU-SKI 43 resulted in a dose dependent
decrease in cell proliferation (Figure 3A). Moreover,Hhat inhibition also significantly reduced proliferation of
all ER positive cells tested (56-95% depending on cell type)
but had no effect on triple negative cells (Figure 3B). Im-
portantly, C2, a compound that is structurally related to
RU-SKI 43 but does not inhibit Hhat activity [45], did not
affect breast cancer cell proliferation (Figure 3C). The
growth defect induced by RU-SKI 43 was rescued, in part,
by Hhat overexpression (Figure 3D-F). These data indicate
that Hhat inhibition by RU-SKI 43 reduces ER positive cell
proliferation.
Hhat overexpression results in increased proliferation of
ER positive cells
We next performed a gain of function experiment by test-
ing the effect of Hhat overexpression. Stable lines of ER
positive (T47D, HCC1428) and ER negative (MDA-MB-
231, BT549) cells expressing either control LacZ or Hhat
Figure 2 Hhat depletion reduces anchorage independent proliferation of ER positive cells. A-F, indicated breast cancer cell lines stably
expressing scrambled or Hhat shRNAs were seeded at 1-2 × 104 cells/well in 24-well ultra-low adherence plates, and cell numbers were quantified
14 days later. Bars represent mean ± SD (n = 3) for all panels. Three independent experiments were performed in duplicate using cells at three
different passages. *P≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Student’s t test.
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expressing Hhat exhibited 56% and 61% increases, re-
spectively, in cell proliferation compared to control cells
expressing LacZ, while overexpression of Hhat in ER nega-
tive cells had no effect on cell proliferation (Figure 3G).
These findings indicate that increased Hhat activity can
enhance ER positive cell proliferation. We then compared
the response of cells stably expressing LacZ or Hhat to in-
creasing concentrations of RU-SKI 43. Hhat overexpres-
sion blunted the inhibitory effect of RU-SKI 43 on cell
proliferation (Figure 3H), supporting the hypothesis
that the effect of RU-SKI 43 is mainly due to inhibition
of Hhat.
RU-SKI 43 does not alter ERα localization or activation
To examine whether Hhat functions through an ERα-
dependent mechanism, we examined the effects of Hhat
inhibition on ERα palmitoylation, localization, and activa-
tion. ERα has been reported to be palmitoylated, and pal-
mitoylation has been proposed to mediate localization of a
subpopulation of ERα to the plasma membrane [46,47].
We used 125I-iodopalmitate, a radioiodinated palmitate
analog that allows for sensitive and robust detection of
palmitoylated proteins in cells [45]. However, we were un-
able to detect incorporation of 125I-iodopalmitate into ei-
ther endogenous or overexpressed ERα in MCF7 cells. Todetermine whether RU-SKI 43 affects ERα localization to
the plasma membrane, the subcellular localization of en-
dogenous ERα was compared in MCF7 cells treated with
either DMSO or RU-SKI 43. ERα localized to the nucleus,
cytoplasm, and plasma membrane, consistent with previ-
ous reports [46,47], and treatment with RU-SKI 43 did not
alter the ERα localization pattern (Figure 4A). Finally, the
ability of estradiol to induce phosphorylation of ERα at
Ser118, a marker of receptor activation [48,49], was not al-
tered by treatment with RU-SKI 43 (Figure 4B). These
data indicate that the effect of the Hhat inhibitor RU-SKI
43 on ER positive cell proliferation is not due to a direct
modulation of ERα localization or activation.
Non-canonical Shh signaling regulates proliferation of a
subset of breast cancer cells
Hhat is the palmitoyl acyltransferase for the hedgehog
family of proteins and is required for efficient Shh signaling
[36,40]. Therefore, we examined whether the effect of Hhat
on proliferation is mediated through hedgehog signaling.
First, we quantified the expression of hedgehog pathway
components in breast cancer cells. Shh mRNA was
expressed in T47D, MCF7, HCC1428, BT474, and MDA-
MB-231 cells (Figure 5A). Ihh was detected in MDA-MB-
231 and BT549 cells, and Dhh was detected in T47D and
MDA-MB-231 cells (Additional file 3: Figure S3A, B).
Figure 3 (See legend on next page.)
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Figure 3 Hhat inhibition with RU-SKI 43 results in decreased proliferation of ER positive cells. A, T47D cells were seeded at 7 × 104 cells/well in
6-well plates. 24 hrs post seeding, cells were treated with either DMSO or the indicated concentrations of RU-SKI 43. Media was changed every 48 hrs
and cell numbers were quantified 2, 4, and 6 days post treatment. B, indicated cell lines were seeded at 5-7 × 104 cells/well in 6-well plates. 24 hrs
post seeding, cells were treated with either DMSO or 10 μM RU-SKI 43. Cell numbers were quantified 6 days post treatment and expressed relative to
growth in DMSO (100 x (RU-SKI 43/DMSO)). C, indicated cell lines were seeded at 5-7 × 104 cells/well in 6-well plates. 24 hrs post seeding, cells were
treated with either DMSO or 10 μM C2. Cell numbers were quantified 6 days post treatment and expressed relative to growth in DMSO. D, cell lysates
from T47D, HCC1428, MDA-MB-231, and BT549 cells stably expressing LacZ or HhatHA were analyzed directly by Western blotting. E-F, (E) T47D and
(F) HCC1428 cells stably expressing LacZ or HhatHA were seeded at 7 × 104 cells/well in 6-well plates and grown in media containing DMSO or 10 μM
RU-SKI 43. Cell numbers were quantified on day 6 and expressed relative to DMSO treated cells. The increase in proliferation between Hhat and LacZ
overexpressing cells in the presence of RU-SKI 43 is 176% and 106%, for T47D and HCC1428 respectively. G, growth curves for T47D, HCC1428,
MDA-MB-231, and BT549 cells stably expressing LacZ or HhatHA. Cells were seeded at 5-7 × 104 cells/well and cell numbers were quantified on day 6.
The increase in proliferation in response to overexpressing Hhat in untreated cells is 56% and 61%, for T47D and HCC1428 respectively. H, T47D cells
overexpressing lacZ or HhatHA were cultured in the presence of DMSO or the indicated concentrations of RU-SKI 43. Cells numbers were quantified
on day 6. Bars represent mean ± SD (n = 3) for all panels. Three independent experiments were performed in duplicate using cells at three different
passages. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001; Student’s t test.
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all cells (Figure 5B, Additional file 3: Figure S3C). Al-
though Smo was expressed in T47D, BT474, and BT549
cells (Figure 5C), little to no Gli-1 or Gli-2 was expressed
in these cells (Figure 5D, Additional file 3: Figure S3D),
suggesting either a cell non-autonomous or non-canonical
role for Shh. Hs578t, which does not respond to Hhat de-
pletion or inhibition (Figures 1J and 3B), was the only cell
line that expressed both Smo and Gli-1 (Figure 5C,D). Re-
pressors of the Shh pathway were only detected in a few
cell lines (hHIP) or at very low levels (Gli-3) (Additional
file 3: Figure S3E, F).
Several breast cancer cell lines (T47D, MCF7, HCC1428,
BT474, and MDA-MB-231) express high levels of Shh
(Figure 5A). To test whether the growth of these cell lines
was dependent on Shh, stable expression of Shh targeting
shRNAs was used to reduce Shh levels (Additional file 4:
Figure S4A-E). No effect of Shh depletion was observed onFigure 4 RU-SKI 43 does not alter localization or activation of ERα. A,
43 for 4 h. Cells were fixed and stained with anti-ERα. Three independent e
B-C, MCF7 (B) or TamR (C) cells were treated with DSMO or 10 μM RU-S
30 minutes prior to lysis. Cell lysates were analyzed directly by Western
were performed in duplicate using cells at three different passages.either anchorage dependent or independent growth in
MCF7, BT474, and MDA-MB-231 cells (Figure 5E-G, J-L).
To investigate whether the lack of response to Shh knock-
down in these three cell lines was due to upregulation
of other hedgehog ligands, levels of Ihh and Dhh were
quantified in Shh depleted cells. Neither Ihh nor Dhh
were detected in MCF7 and BT474 (Ct values above 35)
in either scrambled control or Shh knockdown cells. In
MDA-MB-231 cells, Ihh and Dhh expression was detected
but did not increase after Shh knockdown (Additional
file 4: Figure S4F, G). These data indicate that certain ER
positive cells require Hhat but not Shh for proliferation,
suggesting a Shh independent role for Hhat.
We identified two cell lines, T47D and HCC1428, in
which Shh depletion reduced both anchorage-dependent
(Figure 5H,I) and anchorage-independent proliferation
(Figure 5M,N). We next asked whether decreased Shh sig-
naling was responsible for the reduction in cell proliferationMCF7 cells were cultured in the presence of DSMO or 10 μM RU-SKI
xperiments were performed using cells at three different passages.
KI 43 for 4 h. Cells were treated with ethanol or 17β-estradiol for
blotting with indicated antibodies. Three independent experiments
Figure 5 Analysis of Shh signaling pathway components in breast cancer cells. A-D, expression of (A) Shh, (B) Ptch-1, (C) Smo, and (D) Gli-1
mRNAs in indicated breast cancer cell lines and a control cervical cancer (HeLa) cell line, was measured by qRT-PCR. Expression of individual genes is
shown relative to the expression in HeLa cells, which is set to 1. Bars represent mean ± SD (n = 3). Experiments were performed twice in triplicate. E-I,
indicated breast cancer cells stably expressing scrambled or Shh shRNAs were seeded at 5-7 × 104 cells/well, depending on cell type, in 6-well plates
and cell numbers were quantified on day 6. J-N, indicated breast cancer cell lines stably expressing scrambled or Shh shRNAs were seeded at 1-2 × 104
cells/well in 24-well ultra-low adherence plates, and cell numbers were quantified 14 days later. For E-N, bars represent mean ± SD (n = 3).
Three independent experiments were performed in duplicate using cells at three different passages. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001; Student’s t test.
Matevossian and Resh Molecular Cancer  (2015) 14:72 Page 7 of 15observed upon Hhat inhibition. If RU-SKI 43 reduces cell
proliferation through Shh, then addition of exogenous, re-
combinant Shh(C24II) should rescue the growth of these
cells in the presence of RU-SKI 43. When Shh(C24II) was
added to T47D cells, no effect on cell proliferation was
observed (Figure 6A). However, we and others have
previously shown that in Shh producing cells, the hedge-
hog signaling machinery is saturated and a response toexogenous Shh is only revealed after endogenous Shh
depletion [41,50,51]. Addition of Shh(C24II) rescued,
in part, the growth defect of Shh-depleted T47D cells,
but had no effect on T47D cells expressing the scrambled
control shRNA (Figure 6B). However, treatment of Shh-
depleted cells with RU-SKI 43 further decreased their
growth, suggesting a role for Hhat in addition to Shh sig-
naling (Figure 6B).
Figure 6 Evidence for non-canonical Shh signaling in breast cancer cells. A, T47D cells were cultured in the presence of 1 μM Shh(CII24),
10 μM RU-SKI 43, or both for 6 days. Cell numbers were quantified and normalized to vehicle treated cells (100 x (drug/vehicle)). Bars represent
mean ± SD (n = 3). Experiments were performed twice in triplicate. *P≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Student’s t test. B, T47D cells
were transduced with either a control scrambled or Shh shRNA expressing lentivirus and selected in puromycin. Cells were then cultured in the
presence of 1 μM Shh(CII24), 10 μM RU-SKI 43, or both for 6 days. Cell numbers were quantified and normalized to vehicle treated cells (100 x
(drug/vehicle)). Bars represent mean ± SD (n = 3). Experiments were performed twice in triplicate. **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001;
Student’s t test. C, indicated cell lines were seeded at 5-7 × 104 cells/well in 6-well plates. 24 hrs post seeding, cells were treated with
either DMSO or 0.1 μM LDE225. Cell numbers were quantified 6 days post treatment and expressed relative to growth in DMSO. Bars
represent mean ± SD (n = 3). Three independent experiments were performed in triplicate using cells at three different passages.
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naling is required for the proliferation of these cells, the ef-
fect of LDE-225, a Smo inhibitor, was analyzed. Nanomolar
concentrations of LDE-225 inhibit canonical Shh signaling
[52] and decrease the growth of LDE-225 sensitive tumor
cells [53]. We used LDE-225 at 0.1 μM, a concentration
100x higher than IC50 for binding of LDE-225 to Smo [54],
and found it had no effect on the proliferation of any of the
breast cancer cell lines (Figure 6C), suggesting that Smo-
mediated signaling is absent in these cells. This is consistent
with our finding that T47D and HCC1428 cells have little
to no Gli-1 expression (Figure 5D).Hhat depletion or inhibition reduces proliferation of HER2
amplified cells
ER positive/HER2 positive BT474 cells are sensitive to
Hhat depletion or inhibition (Figures 1, 2, 3 and 7A). We
therefore tested whether Hhat activity is also required for
the growth of HER2 positive cells that are ER negative.
Treatment of MDA-MB-453 and SK-BR-3 cells with
RU-SKI 43 reduced proliferation, while C2 had no effect
(Figure 7B,C, Additional file 5: Figure S5A). Depletion
of Hhat in MDA-MB-453 cells (Additional file 5: Figure S5B)
also led to a significant reduction in proliferation (Additional
file 5: Figure S5C). Thus, Hhat activity is required for the
Figure 7 Hhat inhibition reduces proliferation of HER2 amplified cells. A-C, BT474 (A), MDA-MB-453 (B), and SK-BR3 (C) cells were cultured
for 6 days in the presence of DMSO, RU-SKI 43 alone or in combination with indicated concentrations of lapatinib. Cell numbers were quantified
and normalized to vehicle treated cells (100 x (drug/vehicle). Bars represent mean ± SD (n = 3) for all panels. Each experiment was performed
using three separate passages of cells in triplicate. *P ≤ 0.05; **P≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Student’s t test.
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status. Furthermore, inhibition of both Hhat and HER2 by
combined treatment with RU-SKI 43 and lapatinib re-
sulted in significantly reduced proliferation of BT474 and
MDA-MB-453 cells when compared to treatment with ei-
ther agent alone (Figure 7A,B). Taken together, these data
suggest that Hhat inhibition may be combined with
current HER2 targeted therapies to achieve a more potent
inhibition of breast cancer cell proliferation.
Combined inhibition of Hhat and PI3K/mTOR effectively
reduces breast cancer cell proliferation
Activation of PI3K/mTOR signaling occurs in up to a quar-
ter of both ER positive and HER2 positive breast cancers
[13] and several inhibitors are currently in clinical trials
[55]. Furthermore, increased signaling through this pathway
is also associated with resistance to available therapies [13].Figure 8 Combined inhibition of Hhat and PI3K/mTOR effectively red
BT474 (C) cells were cultured for 6 days in the presence of 10 μM RU-SKI 4
Cell numbers were quantified and normalized to DMSO treated cells (100 x
independent experiments were performed in duplicate using cells at three
Student’s t test.Therefore, we next examined whether RU-SKI 43 could
be effectively combined with PI3K or mTOR inhibitors to
reduce cell proliferation. Combined treatment of ER posi-
tive breast cancer cells with RU-SKI 43 and either the
PI3K inhibitor LY294002 or the mTOR inhibitor rapamycin
resulted in a further decrease in cell proliferation compared
to either drug alone (Figure 8A-C). Thus, simultaneous in-
hibition of Hhat and PI3K/mTOR signaling effectively re-
duces breast cancer cell proliferation.
Hhat depletion or inhibition reduces proliferation of
tamoxifen resistant cells
Tamoxifen is the most widely used hormone therapy for
breast cancer [5]. We therefore investigated whether RU-
SKI 43 could enhance the ability of tamoxifen to reduce ER
positive cell proliferation. Combined treatment with RU-
SKI 43 and 4-hydroxytamoxifen (4-OH Tam) significantlyuces breast cancer cell proliferation. A-C, T47D (A), MCF7 (B), and
3 alone or in combination with 10 μM LY294002 or 10nM rapamycin.
(drug/DMSO)). Bars represent mean ± SD (n = 3) for all panels. Three
different passages. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001;
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compared to either drug alone (Figure 9A-C). We then
tested whether tamoxifen resistant cells retained sensi-
tivity to Hhat inhibition. BT474 cells are tamoxifen resist-
ant (Figure 9D) due to HER2 amplification, but exhibited
reduced proliferation after Hhat knockdown (Figures 1F
and 2D) or inhibition (Figures 3B, 7A and 9D). We next
examined the effect of Hhat inhibition in cells that ac-
quire tamoxifen resistance in the absence of HER2
amplification. We used a tamoxifen resistant clone, TamR,
generated by culturing MCF7 cells in the presence of
10−7 M 4-OH Tam [56], and verified that this clone
does not have HER2 amplification (Additional file 1:
Figure S1). Depletion of Hhat in TamR cells (Additional
file 2: Figure S2F) significantly decreased cell proliferation
(Figure 1G). In addition, treatment of TamR cells with
RU-SKI 43 reduced cell proliferation by 60%, similar to
the effect observed in MCF7 cells (Figure 9C,E). ER activa-
tion in TamR cells was not altered in the presence of
RU-SKI 43 (Figure 4C). Furthermore, the combination
of RU-SKI 43 and tamoxifen led to a more potent inhib-
ition of TamR proliferation (Figure 9E) compared toFigure 9 Tamoxifen resistant cells are sensitive to Hhat inhibition. A-D
were cultured for 6 days in the presence of vehicle, 10 μM RU-SKI 43 alone or
(4-OH Tam). Cell numbers were quantified and normalized to vehicle treated
Three independent experiments were performed in duplicate using cells at th
Student’s t test.RU-SKI 43 treatment alone. Taken together, these data
suggest that Hhat can serve as a target in cells that acquire
tamoxifen resistance through either HER2 amplification
or other mechanisms.
Discussion
In this study, we used genetic and pharmacologic methods
to establish Hhat as a critical regulator of breast cancer
cell growth. Hhat depletion or treatment with the selective
Hhat inhibitor RU-SKI 43 reduced both anchorage-
dependent and anchorage-independent proliferation of
ER positive cells (Figures 1, 2 and 3). Hhat knockdown or
inhibition also reduced the growth of HER2 positive and
tamoxifen resistant cells (Figures 1, 7 and 9). Inhibition of
breast cancer cell growth by RU-SKI 43 was dose dependent
and was rescued by Hhat overexpression (Figure 3). Treat-
ment with C2, a compound that is structurally similar to
RU-SKI 43 but does not inhibit Hhat activity [45], had no
effect on proliferation (Figure 3). We have previously dem-
onstrated that the inhibitory effect of RU-SKI 43 is selective
for Hhat, as this compound does not inhibit palmitoylation
of H-Ras and Fyn, myristoylation of c-Src, or fatty acylation, T47D (A), HCC1428 (B), MCF7 (C), BT474 (D), and TamR (E) cells
in combination with indicated concentrations of 4-hydroxytamoxifen
cells (100 x (drug/vehicle). Bars represent mean ± SD (n = 3) for all panels.
ree different passages. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001;
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family [45]. Overexpressing increasing amounts of Hhat,
but not Porcupine, decreases the inhibitory effect of
RU-SKI 43 on Shh palmitoylation [45]. Moreover, overex-
pression of Hhat reduced the inhibitory effect of RU-SKI
43 on breast cancer cell proliferation (Figure 3H). It is
possible that breast tumors that overexpress Hhat due to
gene amplification might require higher doses of Hhat in-
hibitor. However, our finding that RU-SKI 43 inhibits the
growth of T47D cells, which express relatively high levels
of Hhat compared to other cell lines (Figure 1A), suggests
that Hhat inhibition is a viable approach to reducing
breast cancer cell growth. Taken together, these data sug-
gest that the primary target of RU-SKI 43 is Hhat, and
provide the first identification of Hhat as a novel target in
breast cancer.
Hhat was identified as the palmitoyl acyltransferase for
Shh and the hedgehog family of proteins [36,40], and
Hhat inhibition has been shown to block Shh signaling
[45]. Thus, it was important to monitor expression of
Shh and hedgehog signaling pathway components in
breast cancer cells. There is general agreement between
the findings reported here and in four other studies
[17,19-21] that examined expression levels of Shh path-
way components in four of the same cell lines (T47D,
MCF7, MDA-MB-231, and BT474) that we analyzed: 1)
Shh is expressed in MCF7, T47D, and MDA-MB-2312)
Ptch-1 and 2 are expressed in all four cell lines, and 3) Smo
is expressed in T47D and BT474 but not in MCF7 and
MDA-MB-231 cells. However, in contrast to other studies,
we did not detect Ihh, Dhh, Gli-1 or Gli-2 expression in
MCF7 or T47D cells (Figure 5, Additional file 3: Figure S3).
Differences in Gli expression among the four studies may
be due to differences in culture methods or confluence
state of cells.
Our study addresses two key questions regarding the
role of Shh in breast cancer: 1) Do Shh expressing cells
exhibit an autocrine response to Shh? 2) If so, does this
occur through canonical or non-canonical signaling?
Here, we identify two cell lines, T47D and HCC1428,
where knockdown of Shh reduced anchorage dependent
and independent proliferation (Figure 5). T47D cells can
also undergo increased proliferation in response to ex-
ogenous Shh, but this increase is only evident after en-
dogenous levels of Shh are depleted (Figure 6). However,
T47D and HCC1428 cells neither express Gli-1 (Figure 5)
nor respond to treatment with the Smo inhibitor LDE-225
(Figure 6), indicating the presence of non-canonical Shh
signaling. Others have also noted that treatment with
cyclopamine, a Smo inhibitor, reduces proliferation of cer-
tain breast cancer cells, but that this does not correlate
with Smo expression [19] or inhibition [20]. In this study,
we used LDE-225 at 0.1 μM, a concentration 100x higher
than IC50 for binding of LDE-225 to Smo [54], and foundno effect on proliferation of any of the breast cancer cells
(Figure 6). Taken together, these findings suggest that in
breast cancer cells, canonical Smo mediated signaling is
not operative, and cells that respond to Shh do so via
non-canonical, Smo-independent signaling. This conclu-
sion is supported by multiple recent studies documenting
the existence of non-canonical, Smo-independent Shh sig-
naling pathways in normal and cancer cells [21,41,57-59].
The findings presented here indicate that Hhat has
regulatory roles in addition to Shh signaling. Shh depleted
cells were still sensitive to Hhat inhibition and this
growth defect was not rescued by addition of exogenous
Shh (Figure 6). Moreover, we demonstrate a requirement
for Hhat, but not Shh, for proliferation of multiple ER
positive cells (Figures 1, 2 and 5), consistent with our re-
cent report showing that Hhat can have Shh-independent
functions in pancreatic cancer cells [41]. We speculate
that Hhat has substrates in addition to the hedgehog fam-
ily. Studies in flies have shown that the EGF-like ligand
Spitz is a substrate for Rasp, the Drosophila melanogaster
ortholog of Hhat [60]. Although no Spitz ortholog has
been identified in mammals, and none of the mammalian
EGF family ligands appear to be palmitoylated by Hhat,
our findings of hedgehog-independent roles of Hhat sug-
gest that other substrates exist. We conclude that Hhat
can promote breast cancer cell growth in a Shh independ-
ent manner.
All ER positive cell lines that we tested responded to
Hhat depletion or inhibition by exhibiting decreased pro-
liferation, while triple negative cell lines did not. Multiple
lines of evidence argue against the possibility that Hhat
operates via a direct, ER-dependent mechanism. First, des-
pite reports that ERα is palmitoylated, ERα is unlikely to
be a direct substrate for Hhat. The active site of Hhat is
oriented towards the lumen of the endoplasmic reticulum.
Hhat mediated palmitoylation occurs in the ER lumen and
Hhat only palmitoylates secreted proteins [36,60]. In con-
trast, ERα is localized to the nucleus, cytosol and plasma
membrane, and palmitoylation of ERα is thought to occur
in the cytoplasm [47]. Thus, Hhat could not topologically
access ERα as a substrate as ERα does not enter the
secretory pathway. Second, using 125I-iodopalmitate, a sen-
sitive and robust probe for palmitoylated proteins, we were
unable to detect incorporation of 125I-iodopalmitate into ei-
ther endogenous or overexpressed ERα. Third, RU-SKI 43
treatment did not alter the localization or activation of
ERα, suggesting RU-SKI 43 does not directly affect ERα
function (Figure 4). Fourth, depletion or inhibition of Hhat
can also inhibit the growth of HER2 positive cells that are
ER negative (Figure 7, Additional file 5: Figure S5B), indi-
cating that, in the context of HER2 amplification, Hhat can
modulate cell proliferation independently of ER status.
Increased PI3K/mTOR signaling occurs in up to a
quarter of breast cancers [13] and upregulation of Akt
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and HER2 targeted therapies [12,13]. We observed that
simultaneous inhibition of PI3K/mTOR and Hhat led to a
greater decrease in cell proliferation than with either agent
alone (Figure 8). Similarly, combined treatment with the
Hhat inhibitor and tamoxifen was more effective than ei-
ther drug alone (Figure 9). In addition, we noted that tam-
oxifen resistant cells, either through HER2 amplification
(BT474) or other mechanisms (TamR), maintained sensi-
tivity to Hhat knockdown or inhibition (Figures 1 and 9).
Of note, combined treatment of the TamR cells with the
Hhat inhibitor and tamoxifen was more effective than
RU-SKI 43 alone (Figure 9). Since RU-SKI 43 did not alter
ERα activation in TamR cells (Figure 4C), it is possible
that other pathways induced during selection for tamoxi-
fen resistance may contribute to the increased sensitivity
in this clone. As with all pharmacologic approaches, we
cannot exclude the possibility that off-target effects of
RU-SKI 43, yet to be identified, contribute to the re-
sponse in TamR cells. Taken together, these data under-
score the therapeutic potential of using Hhat inhibitors
alone or in combination with PI3K/mTOR inhibitors or
ER modulators to treat breast cancer and circumvent or
delay resistance to current treatments.
Conclusions
In this study, we used cell lines that represent the het-
erogeneity of breast cancers to establish that Hhat regu-
lates the proliferation of ER positive, HER2 positive, and
tamoxifen resistant breast cancer cells. Smo-dependent
canonical Shh signaling is not operative in any of the cell
lines we tested, and evidence is presented to indicate that
Hhat can regulate breast cancer cell growth independently
of Shh. Our findings identify Hhat as a novel target for
therapeutic intervention in endocrine sensitive and in-
sensitive disease. Together with recent reports of the im-
portance of Hhat in pancreatic and lung cancers [41-44],
this study highlights the potential of Hhat inhibitors for
therapeutic intervention in human malignancies.
Methods
Reagents and antibodies
Lipofectamine 2000® and TRIzol® were obtained from
Invitrogen (Carlsbad, CA). Polybrene was purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Anti-HA antibodies, 17β-estradiol, 4-hydroxytamoxifen,
and puromycin were purchased from Sigma (St. Louis,
MO). Anti-actin was purchased from BD Bioscience (San
Jose, CA). The ErbB2/HER2, ERα, and pSer118 ERα anti-
bodies were purchased from Cell Signaling (Danvers,
MA). LDE-225, LY2940002, and lapatinib ditosylate were
purchased from Selleckchem (Houston, TX). Rapamycin
was obtained from Fisher Scientific (Waltham, MA). Blasti-
cidin S Hydrochloride was obtained from MP Biomedicals(Santa Ana, CA). 0.4% Trypan Blue Solution was purchased
from Cellgro (Manassas, VA). Recombinant human Shh
(C24II) was purchased from R&D Systems (Minneapolis,
MN).
Plasmids
Plasmids encoding short hairpin RNA (shRNA) sequences
for Shh (Clone IDTRCN0000033304), Hhat shRNA 1
(Clone ID TRCN0000035600) and Hhat shRNA 2 (Clone
ID TRCN0000035601), cloned into the pLKO.1 vector,
were purchased from Open Biosystems (Lafayette, CO).
Control pLKO.1 vector, carrying a scrambled shRNA se-
quence, as well as pHRD8.2 and pCMV VSV-G plasmids,
were gifts from Dr. Filippo Giancotti (Memorial Sloan
Kettering Cancer Center, New York, NY). The pLenti6/
V5-GW/lacZ vector was purchased from Invitrogen
(Carlsbad, CA).
Cell culture
Human breast cancer cell lines were gifts from the fol-
lowing colleagues at Memorial Sloan Kettering Cancer
Center, New York, NY: T47D, HCC1428, BT474 (Dr.
Jacqueline Bromberg), MCF7 (Dr. Michael Overholtzer),
BT549 and MDA-MB-231 (Dr. Alan Hall), Hs578t,
CAMA-1, MDA-MB-453, and SK-BR-3 (Dr. Filippo
Giancotti). Cells were grown following ATCC guide-
lines. TamR cells were a gift from Dr. Guangdi Wang
(Xavier University of Louisiana, New Orleans, LA) and
grown in ATCC-formulated Dulbecco’s Modified Eagle’s
Medium, supplemented with 10% FBS and 1.0 × 10−4 M
4-hydroxytamoxifen. All cell lines were authenticated by
the ATCC/Promega Cell Line Authentication Service
using Short Tandem Repeat profiling analysis performed
on July 1, 2014. All cell lines were scored as an exact
match for the corresponding ATCC human cell line ex-
cept for the TamR cell line, which was a 93% match to
parental MCF7 cells.
Lentivirus production and knockdown
Endogenous Shh or Hhat were depleted using shRNA de-
livered to cells via a lentiviral system. Target sequences
are: Shh shRNA(CTACGAGTCCAAGGCACATAT), con-
trol scrambled shRNA(CCTAAGGTTAAGTCGCCCT
CG), Hhat shRNA 1 (GCCACATGGTAGTGTCTCAAA)
and Hhat shRNA 2 (CGTGAGCACCATGTTCAGTTT).
The shRNA-expressing lentiviruses were produced by co-
transfecting confluent 293 T cells in 15 cm plates
with the pLKO.1 shRNA plasmid, the HIV packaging
vector pHRD8.2, and pcDNA3.1 VSV-G, using Lipo-
fectamine2000®. Virus was collected 48 and 72 h later as
follows. First, media was cleared of debris by centrifuga-
tion at 500xg for 5 min. Next, the supernatant was filtered
through a 0.45 μm filter, and centrifuged at 38720 × g for
2 h at 4°C in SS-34 Rotor on RC6C centrifuge (Sorvall,
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pended in ATCC-formulated Dulbecco’s Modified Eagle’s
Medium, supplemented with 10% FBS, and stored at −80°C.
Transduction of cells with lentiviruses was carried out in
the presence of 6 μg/ml Polybrene. Stable cell lines were
produced by transducing target cells with either control
scrambled, Shh, or Hhat shRNA expressing lentiviruses,
followed by selection in puromycin.
Hhat overexpression
The pLenti6/V5-GW/lacZ vector was purchased from
Invitrogen. The lacZ gene was removed by digestion
with SpeI and XhoI, and HhatHA flanked by SpeI and
XhoI sites was ligated into the vector. All constructs
were confirmed by DNA sequencing. Lentivirus was pro-
duced as above and stable cell lines were generated by
transducing target cells with either LacZ or HhatHA ex-
pressing lentiviruses. Cells were selected in Blasticidin S.
Anchorage dependent cell proliferation
Cells were plated in 6-well plates (0.5-1 × 105 cells/well,
depending on cell type). For experiments involving drug
treatment, drugs were added to the media 24 h after
plating and media was refreshed every 48 h. Cells were
grown for up to 6 days, trypsinized and counted with a
hemocytometer.
Anchorage independent cell proliferation
Cells were plated in Corning Costar Ultra-Low attach-
ment 24-well plates (0.1-0.2 × 105 cells/well). For experi-
ments involving drug treatment, drugs were added to the
media 24 h after plating and replenished every 48 h. After
14 days, cells were pelleted, washed with PBS, and treated
with 0.05% Trypsin-EDTA. The trypsin was quenched
with cell culture media, 0.4% Trypan Blue Solution was
added and cells were counted with a hemocytometer.
qRT-PCR
Total RNA was isolated using TRIzol extraction. cDNA
was synthesized using the iScript™ cDNA Synthesis
Kit (Bio-Rad Laboratories, Hercules, CA) following the
manufacturer’s instructions. qRT-PCR was used to deter-
mine expression levels of Hhat, Shh, Ihh, Dhh, Patched-1,
Patched-2, hHIP, Smoothened, Gli-1, Gli-2, Gli-3 and
HPRT using SsoAdvanced™ SYBR® Green Supermix
and the CFX Connect Real Time System (Bio-Rad
Laboratories, Hercules, CA). Gene specific primers are
listed in Additional file 6: Table S1. Hypoxanthine Phos-
phoribosyltransferase 1 (HPRT) was used as an endogen-
ous reference, and the relative expression levels of each
gene were normalized using the comparative Ct method.
Gene expression was normalized to the endogenous refer-
ence given by 2−ΔΔCT.Immunoblot analysis
Cells were lysed in radioimmune precipitation assay
(RIPA) buffer (150 mM NaCl, 50 mM Tris (pH 7.4), 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and
1 mM EDTA). Lysates in sample buffer were electropho-
resed on SDS-PAGE gels, transferred to PVDF mem-
branes, and probed with the indicated antibodies. To
monitor phosphorylation of ERα Ser118, MCF7 or TamR
cells were treated with either DMSO or 10 μM RU-SKI
43 for 4 h. Media was also supplemented with either
ethanol or 200 nM 17β-estradiol for the last 30 min of
incubation. Cells were lysed in RIPA buffer containing
Halt Protease Inhibitor Cocktail and Halt Phosphatase
Inhibitor Cocktail (Thermo Scientific). Lysates in sample
buffer were electrophoresed on SDS-PAGE gels, trans-
ferred to PVDF membranes, and probed with the indi-
cated antibodies.
Indirect Immunofluorescence
MCF7 cells were seeded onto coverslips in 6-well plates
and cultured for an additional 24 h. Cells were treated
with either DMSO or 10 μM RU-SKI 43 for 4 h. Cells
were fixed with 4% paraformaldehyde for 20 min and
permeabilized with 0.2% Triton X-100 for 5 min at room
temperature. Cells were incubated with anti-ERα (Cell
Signaling) for 1 h followed with incubation with a second-
ary antibody (Alexa Flour® 488-conjugated anti-mouse
IgG) for 45 min. Slides were mounted with ProLong® Gold
Antifade (Invitrogen). Images were collected using a Leica
SP5 confocal microscope and analyzed with the Leica
Application Suite software. Images were collected using
the same conditions on the same day ensuring fair side-
by-side comparison.
Additional files
Additional file 1: Figure S1. ER and HER2 expression in breast cancer
cell lines. Cell lysates from indicated breast cancer cells were analyzed
directly by Western blotting for ER and HER2 expression. The experiment
was performed three times using cells at three different passages.
Additional file 2: Figure S2. Hhat knockdown in breast cancer cells.
A-I, T47D (A), MCF (B), HCC1428 (C), CAMA-1 (D), BT474 (E), TamR (F),
MDA-MB-231 (G), BT549 (H), and Hs578t (I) cells were transduced with
either control scrambled or two different Hhat shRNA expressing
lentiviruses and selected in puromycin. qRT-PCR was performed to
determine the relative expression of Hhat mRNA. Bars represent
mean ± SD (n = 3) for all panels. Three independent experiments
were performed in duplicate using cells at three different passages.
*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001; Student’s t test.
Additional file 3: Figure S3. Hedehog pathway expression in breast
cancer cells. A-F, expression of (A) Ihh, (B) Dhh, (C) Ptch-2, (D) Gli-2, (E)
Gli-3, and (F) hHIP mRNAs in indicated breast cancer cell lines and a
control cervical cancer (HeLa) cell line, was measured by qRT-PCR. Expression
of individual genes is shown relative to the expression in HeLa cells, which
is set to 1. Bars represent mean ± SD (n = 3). Experiments were performed
twice in triplicate.
Additional file 4: Figure S4. Shh knockdown in breast cancer cells.
A-E, T47D (A), MCF (B), HCC1428 (C), BT474 (D), and MDA-MB-231 (E)
Matevossian and Resh Molecular Cancer  (2015) 14:72 Page 14 of 15cells were transduced with either control scrambled or Shh shRNA
expressing lentiviruses and selected in puromycin. qRT-PCR was performed
to determine the fold change in Shh expression. F-J, MDA-MB-231 cells
were transduced with either control scrambled or Shh shRNA expressing
lentiviruses and selected in puromycin. qRT-PCR was performed to
determine the fold change in Ihh (F) and Dhh (G) expression. For B,
D, E Bars represent mean ± SD (n = 3). Experiments were performed three
times in triplicate. For panels B, D, and E Bars represent mean ± SD (n = 3).
Three independent experiments were performed in triplicate using cells at
three different passages. For panels A, C, F, and G, bars represent mean ± SD
(n = 2). Two independent experiments were performed in triplicate using
cells at two different passages. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤
0.0001; Student’s t test.
Additional file 5: Figure S5. Hhat depletion reduces proliferation of
MDA-MB-453 cells. A, MDA-MB-453 and SK-BR-3 cells were cultured for
6 days in the presence of DMSO or 5 μM C2. Cell numbers were
quantified and normalized to DMSO treated cells (100 x (drug/DMSO).
Bars represent mean ± SD (n = 3). Three independent experiments
were performed in duplicate using cells at three different passages.
B, MDA-MB-453 cells were transduced with either control scrambled
or two different Hhat shRNA expressing lentiviruses and selected in
puromycin. qRT-PCR was performed to determine the fold change in
Hhat expression. Bars represent mean ± SD (n = 3). Three independent
experiments were performed in duplicate using cells at three different
passages. C, MDA-MB-453 cells stably expressing scrambled or Hhat shRNAs
were seeded at 7x104 cells/well in 6-well plates and cell numbers were
quantified on day 6. Bars represent mean ± SD (n = 3). Three independent
experiments were performed in duplicate using cells at three different
passages. *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001; Student’s t test.
Additional file 6: Table S1. Primers used for qRT-PCR. Primers used for
qRT-PCR for indicated genes.
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